Manchester-based molecular diagnostics firm Yourgene Health plc said on Tuesday its first-half revenues more than doubled to £17.5 million, ahead of previous guidance of at least £15 million.
In a trading update for the six months ended September 30, 2021, Yourgene said it is confident that trading for the full year will remain robust and that full year revenues are therefore likely to exceed current market expectations.
Yourgene CEO Lyn Rees said: “These results demonstrate the breadth and depth of the integrated service offering that Yourgene has created to support its increasingly global customer base.
“I am very proud of the hard work that has driven a strong improvement in performance and created a more diverse platform for future growth.
“Yourgene is now a truly global genomic services and technologies business working in partnership with world leaders in DNA technology to develop and commercialise high quality diagnostic solutions.
“Performing a significant role in the response to the COVID-19 pandemic has also enabled us to expand our capabilities rapidly, not just to capture the current opportunity, but with a very clear focus on our longer-term progress.
“The growth in non-COVID services demonstrates the advantage of having multiple capabilities to deploy flexibly according to our clients’ needs and in rapidly changing market conditions.
“Having invested significantly in our capabilities and business development last year, we look forward with confidence for the rest of this year and at the broader growth prospects ahead.”